Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

The methamphetamine experience: a NIDA partnership.

Hanson GR, Rau KS, Fleckenstein AE.

Neuropharmacology. 2004;47 Suppl 1:92-100. Review.

PMID:
15464128
2.

Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism.

Baucum AJ 2nd, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE.

J Neurosci. 2004 Mar 31;24(13):3436-43.

3.

Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.

Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2002 Mar;300(3):1093-100.

4.

Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.

Volz TJ, Fleckenstein AE, Hanson GR.

Addiction. 2007 Apr;102 Suppl 1:44-8. Review.

PMID:
17493052
5.

Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis.

Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D.

J Neurosci. 2002 Oct 15;22(20):8951-60.

7.

Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity.

Fleckenstein AE, Gibb JW, Hanson GR.

Eur J Pharmacol. 2000 Oct 6;406(1):1-13. Review.

PMID:
11011026
8.

Involvement of nicotinic receptors in methamphetamine- and MDMA-induced neurotoxicity: pharmacological implications.

Escubedo E, Camarasa J, Chipana C, García-Ratés S, Pubill D.

Int Rev Neurobiol. 2009;88:121-66. doi: 10.1016/S0074-7742(09)88006-9. Review.

PMID:
19897077
9.

Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.

Wilhelm CJ, Johnson RA, Lysko PG, Eshleman AJ, Janowsky A.

J Pharmacol Exp Ther. 2004 Sep;310(3):1142-51. Epub 2004 Apr 21.

10.

New insights into the mechanism of action of amphetamines.

Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR.

Annu Rev Pharmacol Toxicol. 2007;47:681-98. Review.

PMID:
17209801
11.

Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6.

Ladenheim B, Krasnova IN, Deng X, Oyler JM, Polettini A, Moran TH, Huestis MA, Cadet JL.

Mol Pharmacol. 2000 Dec;58(6):1247-56.

12.

Detection of methamphetamine neurotoxicity in forensic autopsy cases.

Kitamura O.

Leg Med (Tokyo). 2009 Apr;11 Suppl 1:S63-5. doi: 10.1016/j.legalmed.2009.01.003. Epub 2009 Mar 6. Review.

PMID:
19269222
13.

Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents.

Chipana C, Torres I, Camarasa J, Pubill D, Escubedo E.

Neuropharmacology. 2008 Jun;54(8):1254-63. doi: 10.1016/j.neuropharm.2008.04.003. Epub 2008 Apr 9.

PMID:
18455739
14.

Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications.

Hanson GR, Sandoval V, Riddle E, Fleckenstein AE.

Ann N Y Acad Sci. 2004 Oct;1025:146-50.

PMID:
15542712
15.

Dopamine-induced behavioral changes and oxidative stress in methamphetamine-induced neurotoxicity.

Kita T, Miyazaki I, Asanuma M, Takeshima M, Wagner GC.

Int Rev Neurobiol. 2009;88:43-64. doi: 10.1016/S0074-7742(09)88003-3. Review.

PMID:
19897074
16.

A single methamphetamine administration rapidly decreases vesicular dopamine uptake.

Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2002 Aug;302(2):497-501.

17.

The dopamine transporter: role in neurotoxicity and human disease.

Bannon MJ.

Toxicol Appl Pharmacol. 2005 May 1;204(3):355-60. Review.

PMID:
15845424
19.

Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.

Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J.

J Neurosci. 2001 Dec 1;21(23):9414-8.

20.

Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.

Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2005 Sep;314(3):1087-92. Epub 2005 May 18.

Items per page

Supplemental Content

Write to the Help Desk